Press Releases
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma Appoints New Member to its Board of Directors
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
GT Biopharma Appoints New Member to its Board of Directors
GT Biopharma Appoints New Member to its Board of Directors
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
GT Biopharma Announces Exercise of Warrants
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
